Research Disclaimer: Retatrutide is available exclusively for laboratory and in-vitro research. It is not approved for human use by any regulatory body. This guide is for researchers and laboratory professionals only.
Retatrutide (LY3437943) is the most advanced triple receptor agonist in clinical development for obesity research. Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual), retatrutide activates three receptors simultaneously — GIP, GLP-1, and glucagon — producing Phase 2 weight loss data of 24–26% that no other pharmacological compound has matched in clinical trials.
Sourcing research-grade retatrutide in Europe involves a different set of quality checkpoints than purchasing established clinical compounds. This guide covers the supply chain, what quality markers to require, how to evaluate a supplier, and which formats best suit different research objectives.
Table of Contents#
- Why Quality Verification Is Critical for Retatrutide
- What to Require from Any Supplier
- Available Formats: Vials, Kits, and Pens
- ZPHC Retatrutide: What Sets It Apart
- EU Shipping and Discreet Delivery
- Price Guide: What Research-Grade Retatrutide Costs in Europe
- Frequently Asked Questions
Why Quality Verification Is Critical for Retatrutide#
Retatrutide is a complex 37-amino acid peptide modified with a fatty acid chain for extended half-life and subcutaneous absorption. Its synthesis requires solid-phase peptide synthesis (SPPS) under controlled conditions, followed by purification chromatography and lyophilization. The manufacturing complexity is substantially higher than simple peptides like BPC-157 or Ipamorelin.
Because retatrutide has no approved commercial form (unlike semaglutide which is available as Ozempic/Wegovy), the entire research supply chain is compounded — which means quality varies enormously between manufacturers. Common issues with low-quality retatrutide include:
- Incorrect sequence or truncated fragments — synthesis errors producing a peptide that does not activate all three receptors
- Low purity — HPLC purity below 95% indicates significant impurity load that confounds research results
- Incorrect concentration — vials labeled 10 mg may contain 6–8 mg of active compound
- Degraded peptide — inadequate lyophilization or improper cold chain produces denatured, inactive material
Any of these defects render the research compound scientifically unreliable and its results uninterpretable.
What to Require from Any Supplier#
Before purchasing retatrutide from any supplier, require documentation of the following:
1. HPLC Purity Certificate (COA)#
The certificate of analysis should show HPLC chromatography data with ≥98% purity. Any supplier who cannot provide a batch-specific HPLC COA should be disqualified. The COA should identify the testing laboratory, the batch number, the retention time, and purity percentage.
2. Mass Spectrometry Identity Confirmation#
HPLC alone confirms purity but not molecular identity. Mass spectrometry (ESI-MS or MALDI-TOF) confirms that the measured molecular weight matches retatrutide's expected molecular weight (~4,723 Da). A complete COA includes both HPLC and MS data.
3. Verified EU Stock#
EU-warehoused stock eliminates customs risk and ensures cold chain continuity. Retatrutide shipped from Asian manufacturers through customs checkpoints faces temperature excursion risk and potential seizure risk that EU-based stock avoids.
4. Batch Traceability#
Reputable suppliers maintain batch numbers and can trace product to a specific production lot. This is standard practice in pharmaceutical quality control and should be standard for research compounds.
5. Janoshik or Equivalent Third-Party Testing#
Janoshik Analytical (based in Czech Republic) is the EU research peptide community's reference laboratory for independent HPLC verification. A Janoshik COA is a third-party verification that the manufacturer's own certificate is accurate. This is the gold standard for European research peptide sourcing.
Available Formats: Vials, Kits, and Pens#
Research-grade retatrutide is available in three distinct formats, each suited to different research frameworks:
Lyophilized Vials#
Lyophilized (freeze-dried) vials are the standard research peptide format. The active compound is in powder form, stable at refrigerator temperature, and must be reconstituted with bacteriostatic water before use.
Vial sizes available:
- 5 mg — dose-escalation phase, low-volume protocols
- 10 mg — standard single-use per week at 8–10 mg dosing
- 15 mg — one-to-two doses at 8–12 mg protocol
- 20 mg — multi-use vial for extended protocols
- 30 mg — highest density per vial; multi-dose protocols
Who vials suit: researchers who require flexibility in concentration and dosing volumes, and have access to BAC water and peptide syringes.
Multi-Dose Kits#
Pre-packaged multi-vial kits reduce per-dose cost and ensure consistent batch across a full research run. ZPHC multi-dose kits:
- 5 × 10 mg kit (50 mg total) — full 6-week escalation + initial maintenance
- 5 × 12 mg kit (60 mg total) — 5 weeks at 12 mg/week maintenance
- 10 × 10 mg kit (100 mg total) — 12-week research segment at 8 mg/week
Aqueous Pens (Ready-to-Inject)#
Pre-formulated aqueous retatrutide in an injection pen eliminates reconstitution. The ZPHC Retatrutide AQ pen format mirrors the format of approved GLP-1 pens:
- 30 mg pen — multi-dose pen pre-loaded with retatrutide in aqueous solution
- 60 mg pen — higher total dose per pen unit
Who pens suit: research setups where reconstitution equipment (BAC water, syringes, storage vials) are unavailable or impractical; where injection precision via dose-dial is preferred.
ZPHC Retatrutide: What Sets It Apart#
ZPHC (Zhengzhou Pharmaceutical Co.) is one of the few manufacturers producing retatrutide at research grade with verifiable quality documentation. Their retatrutide line is notable for:
Verified synthesis: ZPHC produces their peptides via solid-phase synthesis with in-house HPLC purity testing. The COA accompanying each batch is batch-specific, not generic.
Multiple formats: ZPHC offers vials, kits, and aqueous pens — a range that no single competitor currently matches for retatrutide specifically. The pen format in particular requires more sophisticated formulation chemistry than lyophilized vials and is offered by very few manufacturers.
EU-distributed: ZPHC products are distributed through EU-based logistics partners, eliminating customs unpredictability common with Asia-direct orders.
Janoshik-verified: JuicedPharma independently submits ZPHC retatrutide batches to Janoshik for third-party verification before accepting stock. Results are published on the product page.
EU Shipping and Discreet Delivery#
JuicedPharma dispatches from an EU warehouse with the following logistics features:
- Domestic EU shipping: standard 2–4 day delivery to most EU member states; 1–2 days to NL, DE, BE, LU
- Discreet packaging: plain outer box with no product identification; inner cold pack for temperature stability during transit
- Trackable shipments: DHL Express and PostNL tracked, with tracking number provided after dispatch
- Cold chain: peptides shipped with refrigerated inner pack maintaining ≤15°C for up to 72 hours transit time; lyophilized vials tolerate transit temperature excursions without degradation
- Customs-clear: EU warehouse dispatch means no customs clearance, no import duties for EU buyers, and no risk of seizure at borders
Price Guide: What Research-Grade Retatrutide Costs in Europe#
Research-grade retatrutide is priced by total milligrams of active compound, format complexity, and verification level. Approximate EU market pricing (JuicedPharma current pricing):
| Format | Size | Price |
|---|---|---|
| Lyophilized vial | 5 mg | €38 |
| Lyophilized vial | 10 mg | €76 |
| Lyophilized vial | 20 mg | €138 |
| Lyophilized vial | 30 mg | €197 |
| Multi-dose kit | 5 × 10 mg (50 mg) | €345 |
| Multi-dose kit | 5 × 12 mg (60 mg) | €410 |
| Aqueous pen | 30 mg | €189 |
| Aqueous pen | 60 mg | €359 |
Cost per mg: ranges from approximately €6–8/mg for standard vials. Premium for the pen format reflects formulation complexity. Kit pricing typically offers 5–10% savings over equivalent individual vials.
Frequently Asked Questions#
Is retatrutide legal to buy in Europe? Retatrutide is not a scheduled or controlled substance in EU member states. Purchasing it as a research compound for laboratory use is legal. It is not licensed as a medicine, meaning it cannot be dispensed through pharmacy channels or used for clinical treatment. Researchers and laboratories may procure it as a research compound under their institutional frameworks.
How should I store retatrutide after it arrives? Refrigerate immediately upon receipt at 2–8°C. Lyophilized vials can be stored at this temperature for their full 24-month shelf life. Do not freeze. Keep away from direct light.
What is the best format for a multi-week research protocol? For extended (12+ week) protocols, the multi-dose kit provides the best value and batch consistency. For flexible shorter protocols or initial pilot studies, individual vials (10 mg or 20 mg) provide the most adaptable format.
What's the difference between ZPHC Retatrutide and generic brands? ZPHC provides batch-specific COA data, manufactures retatrutide in multiple verified formats, and their product is distributed through EU channels with cold chain maintained. Generic or unnamed manufacturer peptides typically lack independent purity verification and batch traceability.
Does JuicedPharma offer Janoshik COAs for their retatrutide stock? Yes. All ZPHC retatrutide batches stocked at JuicedPharma are Janoshik-verified before being listed for sale. COAs are available on the product page.
